

1.0.7 DOC EIA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

Headaches

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

3. **Guideline development: before consultation (to be completed by the developer before draft guideline consultation)**

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

n/a

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

No equality issues identified

3.3 Were the Committee's considerations of equality issues described in the consultation document, and, if so, where?

n/a

1.0.7 DOC EIA

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Topiramate is teratogenic, so cannot be used in pregnancy or for women who may become pregnant. This could make it difficult for women of child bearing age to access prophylactic treatment for migraine, so the committee took this into account and made the recommendation that either topiramate or propranolol should be offered as a first line treatment. The committee highlighted the teratogenicity of topiramate in the recommendation as they felt that this was an important consideration when offering prophylactic medication, and recommended that women of child bearing age who are offered topiramate should also be offered contraception if needed.

We also specified pregnant women as a subgroup in the protocol, but we didn't find any evidence for this group.

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

No

1.0.7 DOC EIA

Completed by Developer CGUT Nicole Elliott

Date 2 9.06.15

Approved by NICE quality assurance lead: Sharon Summers-Ma

Date 26 November 2015

1.0.7 DOC EIA

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

no

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

n/a

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

n/a

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.2, 4.3 and 4.4, or otherwise fulfil NICE's obligations to advance equality?

n/a

1.0.7 DOC EIA

4.5 Have the Committee's considerations of equality issues been described in the final guideline document, and, if so, where?

n/a

Updated by Developer: Lorraine Taylor - CGUT

Date 14/10/2015

Approved by NICE quality assurance lead Sharon Summers Ma
Date 26 November 2015

1.0.7 DOC EIA